Saturday, October 11, 2008

MedX Health Brings new Laser to US Market

MedX Health, a company headquarted in Mississauga, Ontario, has announced FDA approval of their Oralase diode laser. The device uses a GaAlAs diode to produce a laser light that cuts inflammation and consequently, pain after dental procedures.

The 200mw device has a rechargeable battery and different tips.

Here is the info from the press release:

About Oralase(TM)
Oralase is an ergonomically designed portable low level
laser device that offers dental staff a proven, drug-free
solution to reduce or eliminate pain and accelerate soft
and hard tissue repair. Oralase is designed to effectively
control pain and decrease swelling from invasive dental
procedures as well as
stimulate healing.

About Low-Level Laser Therapy

For more than 35 years, LLLT has been used in Europe,
Australia, Asia and Russia for the treatment of pain
and tissue repair. MedX's LLLT was approved
in Canada in 1999 and in the United States in 2002.
LLLT uses a specific type of light to penetrate the
skin's surface and underlying tissues to stimulate
the body's natural repair processes. The result
is faster healing and reduced pain, swelling and
inflammation. The technology has advanced laser therapy
significantly, and Oralase embodies the new
generation of photobiomodulation technology for
health care today.
About MedX Health Corp. ----------------------- MedX is a leading North American developer and manufacturer of low level laser and light medical devices, including dental, rehabilitation and wound care products. MedX is the world's only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for and bringing the non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments.

MedX plans to use the proceeds from its recent public offering to expand its distribution network; support its marketing program; continue development of new dental, rehabilitation and wound care products; undertake research and development for wound care products; and for working capital purposes. In particular, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its "Photobandage", a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development, marketing and sales. For more information, visit


  1. "Prolo" is short for proliferation, because the treatment causes the proliferation of new ligament tissue in areas where it has become weak. It involves the injection of natural substances, often as basic as dextrose and lydocaine into the area
    of pain.
    Internet Marketing

  2. I recently came accross your blog and have been reading along. I thought I would leave my first comment. I dont know what to say except that I have enjoyed reading. Nice blog. I will keep visiting this blog very often.